MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04392648 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-01-14

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of TAK-573 when used with dexamethasone and in combination with bortezomib, pomalidomide, or cyclophosphamide, in participants with RRMM.

Conditions

  • Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG

TAK-573

TAK-573 intravenous infusion.

DRUG

Pomalidomide

Pomalidomide capsules orally.

DRUG

Bortezomib

Bortezomib injection subcutaneously.

DRUG

Cyclophosphamide

Cyclophosphamide tablets orally.

DRUG

Dexamethasone

Dexamethasone tablets orally.

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-24
Primary Completion
2023-11-10
Completion
2023-11-10
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04392648 on ClinicalTrials.gov